|
May 23
|
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
|
|
May 23
|
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?
|
|
May 23
|
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?
|
|
May 23
|
EXEL vs. ARGX: Which Stock Is the Better Value Option?
|
|
May 23
|
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
|
|
May 23
|
Solid Earnings Reflect Exelixis' (NASDAQ:EXEL) Strength As A Business
|
|
May 23
|
Product Performance, Big Money Lift Exelixis
|
|
May 22
|
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
|
|
May 22
|
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
|
|
Apr 11
|
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
|
|
Apr 11
|
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
|
|
Mar 13
|
Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?
|
|
Mar 12
|
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
|
|
Mar 12
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
|
Mar 1
|
Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?
|
|
Feb 28
|
Exelixis focuses on future growth despite COSMIC-313 trial challenges
|
|
Feb 26
|
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors
|
|
Feb 25
|
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
|
|
Feb 25
|
Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia
|
|
Feb 24
|
EXEL or TECH: Which Is the Better Value Stock Right Now?
|